Commercial Readiness: The ROI Of Defragmented Supply Chains

Manufacturing processes may be proven and regulatory pathways clear, yet many advanced therapy programs reach launch with a supply chain built one vendor and one decision at a time. The costs of that history rarely appear as a single budget line. They surface when a temperature excursion pulls several organizations into separate quality systems, or when qualification work is repeated because processes were never designed to operate together. This analysis considers how commercial scale magnifies weaknesses that earlier stages concealed, and what the common focus on simplification may overlook about the return on defragmentation. It also asks where that return becomes visible over the life of a commercial program. Explore the reasoning behind the argument.